secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immuneering Corp (IMRX)
CIK:        0001790340
Form:       8-K
Filed at:   2021-11-09T23:59:59+00:00
Accession:  0001558370-21-015144
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immuneering Q3 net loss $8.5M ($0.47/sh); cash $159.6M; IND for IMM-1-104 in Q1 2022
--------------------------------------------------------------------------------

- Net loss attributable to common stockholders $8.5M vs $4.4M in Q3 2020; diluted EPS $(0.47).
- Cash and marketable securities $159.6M as of Sep 30, 2021, up from $37.1M at Dec 31, 2020.
- Completed upsized IPO of 8.625M shares at $15.00 each, gross proceeds $129.4M.
- IND filing for dual-MEK inhibitor IMM-1-104 expected Q1 2022; Phase 1 trial in 1H 2022.
- R&D expenses $6.2M (up from $4.1M); G&A $2.6M (up from $0.7M) due to IPO prep and headcount.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1790340/000155837021015144/0001558370-21-015144-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1790340/000155837021015144/imrx-20211109x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-21-015144

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer